Praxis Precision Medicines Partners in GeneDx's Initiative to Transform Pediatric Epilepsy Diagnosis
- Praxis Precision Medicines collaborates on a Patient Access Program to improve genetic diagnosis in pediatric epilepsy.
- The initiative aims to increase genetic diagnosis rates from 19% to nearly 25% for seizure patients.
- Enhanced access to whole exome sequencing will support personalized treatments and advance research in epilepsy genetics.
Improving Pediatric Epilepsy Diagnosis through Collaborative Innovation
GeneDx, a leader in genomic insights, has launched a groundbreaking Patient Access Program aimed at transforming the diagnostic landscape for pediatric epilepsy. This initiative, in collaboration with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, addresses the significant challenges faced by families navigating the lengthy 5–8-year journey to obtain definitive genetic diagnoses for children with epilepsy. The project acknowledges that while over 700 genes are linked to seizure disorders, most commercial gene panels only test for less than 50% of these, making whole exome sequencing a critical tool for accurate diagnosis. By enhancing access to this advanced testing method, the program is poised to improve the diagnostic yield significantly—offering genetic diagnoses to nearly 25% of seizure patients, compared to just 19% from traditional panels.
The initiative is particularly timely given the American Epilepsy Society and the National Society of Genetic Counselors’ recommendations for whole exome sequencing as a first-line approach for unexplained epilepsy. Despite the clear clinical advantages, disparities in access to genetic testing have historically impeded equitable care, resulting in prolonged diagnostic timelines and emotional distress for families. GeneDx's program is designed to lower these barriers, ensuring that more children can receive timely and accurate diagnoses. This effort not only promises to alleviate the burdens on families but also seeks to contribute to the broader understanding of genetic factors in epilepsy, which affects nearly half a million children under 18 in the United States.
Melanie Duquette, Chief Growth Officer of GeneDx, emphasizes the significance of this initiative in uncovering the genetic underpinnings of epilepsy. By facilitating access to whole exome sequencing, the program aims to provide critical insights that can lead to personalized treatments and therapies tailored to individual patients. The data generated through this initiative will also enrich GeneDx's extensive database of over 700,000 exome and genome results, bolstering ongoing research into gene-disease relationships and advancing the biopharma sector’s understanding of seizure-related conditions. As the healthcare landscape evolves, such collaborative efforts highlight the vital role of genetic testing in improving patient care and outcomes.
In addition to enhancing diagnostic capabilities, the Patient Access Program stands as a testament to the power of partnerships in the biopharmaceutical industry. By pooling resources and expertise, GeneDx and its partners are not only addressing immediate patient needs but also laying the groundwork for future innovations in treatment. As the program unfolds, it has the potential to reshape the approach to pediatric epilepsy, ensuring that children receive the care they deserve in a timely manner and paving the way for breakthroughs in personalized medicine.